Quarterly report [Sections 13 or 15(d)]

STOCK OPTIONS

STOCK OPTIONS

3 Months Ended

Mar. 31, 2025

Share-Based Payment Arrangement [Abstract]

NOTE 11- STOCK OPTIONS

A summary of the status of the Company’s outstanding stock options and changes during the periods is presented below:

	Shares available to purchase			Weighted Average		Weighted Average Remaining Contractual		Aggregate
	with options			Exercise Price		Term (in years)		Intrinsic Value
Outstanding, December 31, 2024		3,640,000		$	0.17		9.02	$	-
Issued		-			-		-
Exercised		-			-		-		-
Cancelled		(37,500	)		0.17		-		-
Expired		-			-		-		-
Outstanding, March 31, 2025		3,602,500		$	0.17		8.78	$	-

Exercisable, March 31, 2025		1,541,448		$	0.17		8.76	$	-

Outstanding, December 31, 2023		-		$	-		-	$	-
Issued		4,660,000			0.17		9.76		-
Exercised		-			-		-		-
Cancelled		-			-		-		-
Expired		-			-		-		-
Outstanding, March 31, 2024		4,660,000		$	0.17		9.76	$	-

Exercisable, March 31, 2024		590,624		$	0.17		9.76	$	-

The fair value of stock options granted and vested during the three months ended March 31, 2025 was zero and $82,057, respectively.

The fair value of stock options granted and vested during the three months ended March 31, 2024 was $731,548 and zero, respectively.

The compensation expense attributed to the issuance of stock options is recognized as they are vested. Total compensation expense related to the stock options was $82,057 and $92,719 for the three months ended March 31, 2025 and 2024, respectively, and was included in compensation expense on the statement of operations. As of March 31, 2025, there was $312,565 in future compensation cost related to non-vested stock warrants.

The aggregate intrinsic value as of March 31, 2025 is zero for total outstanding and exercisable warrants, which was based on our estimated fair value of the Class A common stock of $0.05, had all option holders exercised their options as of that date, net of the aggregate exercise price.